Counteracting Bone Loss Associated With Breast Cancer Therapies CME

Author Information and Disclosures

Release Date: August 15, 2008; Valid for credit through August 15, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Novartis
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss disease and patient factors that influence the selection of adjuvant therapy for patients with hormone-sensitive breast cancer
  2. Discuss the safety profiles of various agents used for the treatment of hormone-sensitive breast cancer, including effects on bone loss
  3. Determine the most appropriate therapy for the treatment of postmenopausal women with hormone-sensitive breast cancer, as well as any prophylactic measures to prevent unwanted side effects, on the basis of current data
Authors and Disclosures

Jenny C. Chang, MD
Disclosure: Jenny C. Chang, MD, has disclosed that she has received grants for clinical research from AstraZeneca, Aventis, Genentech, GlaxoSmithKline, and Merck.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.


Ammar Hasan, PharmD
Disclosure: Ammar Hasan, PharmD, has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.